Outsourcing and Biomanufacturing Challenges for Emerging TherapiesA Roundtable Discussion at BIO 2016's BPI Theater

摘要

The biopharmaceutical industry is increasingly interested in a range of emerging therapies. "We're really starting to get beyond the monoclonal antibody," said Patricia Seymour (senior consultant with BioProcess Technology Consultants) in her introduction to a lunchtime BPI Theater roundtable at the 2016 Biotechnology Industry Organization annual convention in San Francisco, CA, this past June. The discussion brought together three industry insiders for strategic outsourcing to talk about emerging biotherapies and their manufacturing challenges:Mark Angelino (senior vice president of pharmaceutical sciences at bluebird bio)